Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2018 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling, with the three conditions met. Let's analyze the transcript. The company is Surmodics, a medical device company. Key counterparties: Abbott (for SurVeil drug-coated balloon), and potential partners for other products. Also customers for coatings. Management discusses Abbott partnership extensively. They have an agreement with Abbott for worldwide commercialization rights for SurVeil. They supply the product, collaborate on development, clinical trials, regulatory. Abbott has options for other programs. Management says "Our collaboration with Abbott team on ongoing development for SurVeil and the partnership itself is going exceptionally well." They talk about the TRANSCEND trial progressing, enrollment, etc. They mention revenue from Abbott of $1.7 million in quarter, and guidance includes $4-4.5 million for fiscal 2018. They discuss deferred revenue and how revenue will be recognized over time tied to study costs. They talk about Abbott's deep expertise and worldwide market coverage. This is a counterparty that is already contracted, revenue flowing, and the trial is ongoing. But is management narrating Abbott's own expansion? Abbott is a large company, but the focus is on the SurVeil product development and commercialization. Management describes the partnership and the trial progress, but does it describe Abbott's own ramps, launches, rollouts, etc.? They mention Abbott's worldwide market coverage, but not specific plans of Abbott to scale up. The trial is being run by Surmodics and Abbott together. The revenue from Abbott is tied to the study costs, not to Abbott's sales. The product is not yet approved. So the counterparty's trajectory is not about Abbott's own business expansion; it's about the joint development and regulatory approval. The company is not yet selling to end customers; it's receiving milestone payments from Abbott. So the "counterparty" here is Abbott as a partner, but the growth is not Abbott's own business scaling; it's the product development process.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.